VIB’s antiviral treatment developer has closed its series A round following a $22.6m extension backed by the research institute, V-Bio Ventures and Vives Inter-University Fund.

UCB’s corporate venture capital unit has helped the antiviral treatment developer close its series A round, joining a $22.6m extension.

Salesforce Ventures and Optum Ventures helped the healthcare network technology provider push its valuation above $1.6bn and its total funding to near $200m.

Insight Partners and Scale Venture Partners co-led a series C round for the GV-backed stroke detection software provider, taking its total funding to $150m.

Eli Lilly and Novartis Venture Fund participated in a round that will support the progress of Amphista's protein degradation drug candidates toward clinical trials.

Forbion and Gilde Healthcare have co-led a $53m series B round for Dundee spinout Amphista, which is working on targeted protein degradation technology.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The kidney healthcare provider boosted its total funding to more than $220m in a round led by Alphabet's CapitalG subsidiary.

Tencent and Gilead Sciences took part in a round that will fund clinical trials for three of Vaccitech's vaccine product candidates.

OSF Healthcare Ventures contributed to a $102m series D round for Inflammatix, a developer of diagnostics systems for detecting infections.